ARTICLE | Clinical News
CNV2197944: Phase II started
July 15, 2013 7:00 AM UTC
Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a double-blind, placebo-controlled, crossover, Hungarian Phase II trial to evaluate 75 mg oral CNV2197944 thrice daily for 3 weeks in about 16...